Research & Development

Avalife Group Company Biologics and Vaccines is a Cape Town based biotechnology company strategically directed, supported and capitalized by Avacare Healthcare Group and the Industrial Development Corporation (IDC) of South Africa.

It was founded in 2014 by Steven G. Reed (PhD) and Erik Iverson (JD, LLM), both of the Infectious Diseases Research Institute (IDRI) in Seattle.

Avalife Group Company drives a business strategy focusing on product development, bulk adjuvant manufacturing, and supply and distribution of key biologicals to address unmet healthcare needs. Through international partnerships and local capacity building, Avalife Group Companhy has established the first ever adjuvant production and formulation technology centre on the African continent.


This centre, in partnership with IDRI, a world leader in adjuvant development, focuses on next generation vaccine adjuvants, which are not only geared at preventing disease, but have therapeutic value.

Avalife Group Company laboratories are based at the South African Medical Research Council (SAMRC) Medicina Campus in Cape Town. Product development and analytical laboratories, furnished with specialised equipment for formulation, downstream processing and analytical capabilities, are conveniently situated near the Biomedical Research and Innovation Platform (BRIP) of the SAMRC.

The laboratories are currently operated according to GLP principles and will seek appropriate accreditation when operations are expanded to larger premises.